Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
I am looking for
added new label for I am looking for
Advanced Filters
Found 564 clinical trials
APG-1387 in Patients With Advanced Solid Tumors or Hematologic Malignancies

patients with advanced solid tumors and hematologic malignancies. After establishing the maximum tolerated dose (MTD), dose-limiting toxicities (DLTs), and/or recommended phase 2 dose (RP2D), several Ib

  • 04 Oct, 2022
  • 3 locations
A Study of HMPL-306 in Advanced Hematological Malignancies With mIDH

hematological malignancies that harbor IDH mutations.

  • 07 Oct, 2022
  • 7 locations
Clinical Study of CD38 CAR-T Cells in the Treatment of Hematological Malignancies

Clinical Study on the Safety and Effectiveness of CD38 CAR-T Cells in the Treatment of CD38-positive Hematological Malignancies

  • 23 Mar, 2022
  • 1 location
Clinical Study of CLL1 CAR-T Cells in the Treatment of Hematological Malignancies

Clinical Study on the Safety and Effectiveness of CLL1 CAR-T Cells in the Treatment of CLL1-positive Hematological Malignancies

  • 15 Mar, 2022
  • 2 locations
Multi Cohort Study of Tazemetostat in Combination With Various Treatments For R/R Hematologic Malignancies

This phase 1b/2 trial studies how safely the EZH2 inhibitor tazemetostat works with other therapies in various hematological malignancies. Tazemetostat has been found to be a safe and effective

  • 10 Mar, 2022
  • 1 location
  • 15 Feb, 2021
  • 1 location
T Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation Conditioned With a Reduced Intensity Regimen in Patients With Hematologic Malignancies and Aplastic Anemia

The main purpose of this study is to learn if a new combination of chemotherapy, in combination with low-dose radiation, will be safe for the patient, and at the same time provide the best opportunity to cure the bone marrow cancer. The combination of chemotherapy and radiation described in the …

  • 21 Mar, 2022
  • 2 locations
VEN-OM: Phase IB/II Study Of Safety And Efficacy Of Venetoclax When Combined With Escalating Doses Of Omacetaxine In Patients With Relapsed/Refractory Hematologic Malignancies Failing Treatment With Venetoclax-Containing Regimens (VEN-OM)

participants with relapsed/refractory hematologic malignancies including those failing treatment with venetoclax-containing regimens. Treatment plan will consist of an induction phase, followed by a

  • 13 Oct, 2022
  • 1 location
Infusion of Donor Derived Cytokine Induced Killer (CIK) Cells in Hematological Patients Relapsed After Haploidentical Stem Cell Transplant

The haematological neoplasia relapse is the cause of higher mortality after allogeneic stem cell transplantation (HSCT). When transplantation fails the most common therapeutic strategy is to increase the antitumor activity of the donor's immune system through the infusion of donor Lymphocytes (DLI). The use of DLI may limit the relapse, …

  • 01 Jan, 2022
  • 1 location
A Study of Itacitinib for the Prevention of Cytokine Release Syndrome Induced by Immune Effector Cell Therapy

years or older and who are planning to receive an approved immune effector cell (IEC) therapy for hematologic malignancies.

  • 06 Jun, 2022
  • 9 locations